Tech Company Financing Transactions
Consano Bio Funding Round
Consano Bio closed a $15 million funding round on 10/5/2026. Backers included private investors.
Transaction Overview
Company Name
Announced On
10/5/2026
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Summit Drive
Burlington, MA 01803
USA
Burlington, MA 01803
USA
Phone
Undisclosed
Website
Email Address
Overview
Consano Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of painful and debilitating orthopedic conditions through a new class of disease-modifying therapeutics that target the drivers of disease, rather than the symptoms. Consano Bio's lead investigational program, C-1101, is being developed as a potential first-in-class, non-opioid pharmaceutical therapy for chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The therapy is designed to deliver a high concentration of proteins from human platelets directly to the site of injury to modulate inflammation and promote localized cell and tissue repair.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Hall
Chief Marketing Officer
Mark Versavel
Chief Operating Officer
Jennifer Schmitke
VP - Finance
Rahul Bansal
Browse more venture capital transactions:
Prev: 10/5/2026: Buntar Aerospace venture capital transaction
Next: 10/5/2026: Etched venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs